Compare Robinhood Markets, Inc. (HOOD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs TG Therapeutics Inc — how do they compare? Robinhood Markets, Inc. trades at $109.02 (market cap $96.21B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Robinhood Markets, Inc. is far larger — about 11.8× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and TG Therapeutics Inc for 16 Days on average.
| HOOD | TGTX | |
|---|---|---|
Market Cap | $96.21B | $8.16B |
Volume | 22,572,153 | 1,735,121 |
Sector | Financials | Health |
52-Week High | $152.46 | $59.06 |
52-Week Low | $65.16 | $26.94 |
Typical Hold Time | 75 Days | 16 Days |
Enterprise Value | $102.75B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $107.01, down 2.28% today, amid a bullish technical setup with support at $105 and resistance at $109. The company reported strong 2025 results with revenue of $4.47 billion and net income of $1.88 billion, though Q1 2026 earnings missed expectations. Recent news highlights expansion into 24/7 stock trading and new product launches aimed at boosting engagement.
Outlook remains positive with a consensus price target of $137.53, implying 28% upside, supported by 77% analyst buy ratings. Key risks include high valuation multiples (P/E 47.35) and reliance on retail trading growth, while regulatory scrutiny and market volatility pose challenges to sustained momentum.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
